Cambium Bio Ltd · ASX:CMB
Cambium Bio — Shareholder Meeting (November 2019)
16 slides from Cambium Bio's shareholder meeting presentation, Nov 21, 2019
Slide 1: 2019 AGM CEO Presentation
2019 AGM CEO Presentation Developing the next generation of pain management and inflammation therapeutics November 2019 Regeneus Ltd (ASX:RGS)
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This Presentation contains certain statements which constitute forward-looking statements or information ("forward-looking statements”). These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the g
Slide 3: Regeneus Overview
Regeneus Overview Regeneus (ASX:RGS) is a global clinical-stage regenerative medicine company based in Australia Focus on the growing pain and inflammation market Significant unmet clinical need for regenerative, non-invasive, pain treatments that do not rely on opioid treatments Leader in autologou
Slide 4: Mesenchymal Stem Cells (MSCs)
Mesenchymal Stem Cells (MSCs) Cells that can differentiate into other cells types, including bone, cartilage, muscle, Can self-renew while maintaining their umbilical cord and fat cells. Originally found multipotency. in bone marrow. Ability to differentiate leads to heal and Application in pain man
Slide 5: Regeneus Platform Technologies
Regeneus Platform Technologies Pain management as key focus area to fill the healing and repair void in the pain treatment market and a solution to opioids. Progenza Sygenus • Uses MSCs to reduce inflammation and heal/repair • Uses bioactive molecules secreted by MSCs to reduce pain and inflammation
Slide 6: R&D Pipeline – Human Health
R&D Pipeline — Human Health Technology ndcoton | coe | tase | rhose2 | Phases | ng age Progenza™ Allogeneic Adipose Osteoarthritis MSC plus MSC Secretions* —_ (Secretome with Neuropathic Pain Bioactive Molecules « & Exosomes) Other Indications Sygenus™ Allogeneic Adipose —_ Burns, Wounds, MSC Secret
Slide 7: Progenza Opportunity in Osteoarthritis (OA)
Progenza Opportunity in Osteoarthritis (OA) $9.5B addressable opportunity in knee OA across Japan, US and EU alone1 OA is pain and inflammation around the joint from ‘wear and tear’ on the tissue Japan is a proven RA market Japan 30M+ patients • Takeda acquired TiGenix for $630m • Astellas bought a
Slide 8: Progenza OA & Current Treatment Market
Progenza OA & Current Treatment Market Progenza fills a gap the current treatment market by providing disease modification and pain relief to address patient symptoms - before surgery is required 50% of diagnosed and prevalent Knee OA is moderate-severe ~5% cartilage loss per year as disease progres
Slide 9: Progenza OA Commercialisation Strategy
Progenza OA Commercialisation Strategy Japan: An accelerated commercialisation pathway and strategic market for Knee OA Expected Clinical Conditional research Approval Final Approval Phase I & II clinical Marketing trials Progenza Knee OA Progenza STEP 2nd clinical Manufacturing Phase II Ongoing eff
Slide 10: Competitors for Knee OA
Competitors for Knee OA Symptomatic pain relief prior to invasive surgical options Pain relief Side effects Non-invasive Disease modifying Short term Long term Progenza ✔ ✔ ✔ ✔ ✔ Acetominophen ✘ ✘ ✘ ✔ ✘ / paracetamol NSAIDs ✔ ✔ ✘ ✔ ✘ Corticosteroids ✔ ✘ ✘ ✔ ✘ Hyaluronic Acid ✔ ✘ ✔ ✔ ✘ Surgery ✘ ✔ ✘
Slide 11: Competitive Allogeneic Clinical Landscape in Knee OA
Competitive Allogeneic Clinical Landscape in Knee OA Progenza’s advantages: pain and cartilage improvement Allogeneic Competition Cell Source Phase Cartilage Company (location) Product KL Grade Pain Relief (IA dose) (location) Improvement Adipose Ph 1 Regeneus (Aus) Progenza (5m) (Australia) 1-3 ✔ ✔
Slide 12: Sygenus Overview
Sygenus Overview Emerging, patented and scalable stem cell technology using MSC secretions Sygenus Platform Technology MSC Secretions • First indication in skin repair • Uses bioactive molecules secreted by MSCs to reduce pain and inflammation, • Pre-clinical stage and to heal and repair cells • Saf
Slide 13: Experienced Board
Experienced Board Leo Lee Prof Graham Vesey CEO & Executive Director Chief Scientific Officer & Executive Director • Former President of Allergan Japan and President of Merck Japan • Regeneus co-founder and founding CEO • Responsible for product origination and development and • 20+ years in pharmac
Slide 14: Company Strategy - Progress
Company Strategy - Progress Revised strategic direction targeting global pain market announced in Q1 FY20 Area of focus Progress Japan commercialisation deal for • Number one priority and focus Progenza OA • Negotiations ongoing, positive outcomes expected in near term • New strategic direction in g
Slide 15: Upcoming Milestones
Upcoming Milestones Japan commercialisation deal for Progenza OA Continue to execute revised company strategy and streamline operations Target Progenza OA product launch in Japan in 2023 New scientific partnership model allows for technology licensing Continued synergies from cost-containment initia
Slide 16: Thank you
Thank you Investor Relations WE-AURegeneus@we-worldwide.com 16